BR112022024553A2 - Composto com atividade inibidora de trpv4 ou um sal farmaceuticamente aceitável do mesmo e seu uso, composição farmacêutica, método para se tratar uma doença da retina acompanhada de distúrbio do fluxo sanguíneo ou distúrbio celular, kit para uso na prevenção ou tratamento das doenças, marcador de doença para uma doença da retina, método para se detectar uma doença da retina, métodos de triagem para uma substância que suprime a expressão do gene de trpv4, uma que reduz o nível de expressão de uma proteína de trpv4 e uma que inibe a atividade de trpv4 e agente para prevenir ou tratar uma doença da retina - Google Patents
Composto com atividade inibidora de trpv4 ou um sal farmaceuticamente aceitável do mesmo e seu uso, composição farmacêutica, método para se tratar uma doença da retina acompanhada de distúrbio do fluxo sanguíneo ou distúrbio celular, kit para uso na prevenção ou tratamento das doenças, marcador de doença para uma doença da retina, método para se detectar uma doença da retina, métodos de triagem para uma substância que suprime a expressão do gene de trpv4, uma que reduz o nível de expressão de uma proteína de trpv4 e uma que inibe a atividade de trpv4 e agente para prevenir ou tratar uma doença da retinaInfo
- Publication number
- BR112022024553A2 BR112022024553A2 BR112022024553A BR112022024553A BR112022024553A2 BR 112022024553 A2 BR112022024553 A2 BR 112022024553A2 BR 112022024553 A BR112022024553 A BR 112022024553A BR 112022024553 A BR112022024553 A BR 112022024553A BR 112022024553 A2 BR112022024553 A2 BR 112022024553A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- trpv4
- retina
- treatment
- protein
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 22
- 201000010099 disease Diseases 0.000 title abstract 17
- 101150098315 TRPV4 gene Proteins 0.000 title abstract 12
- 102000003567 TRPV4 Human genes 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 9
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 210000001525 retina Anatomy 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- 150000003839 salts Chemical class 0.000 title abstract 5
- 230000002401 inhibitory effect Effects 0.000 title abstract 4
- 230000017531 blood circulation Effects 0.000 title abstract 3
- 238000012216 screening Methods 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000000126 substance Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052572P | 2020-07-16 | 2020-07-16 | |
| PCT/JP2021/026829 WO2022014707A1 (ja) | 2020-07-16 | 2021-07-16 | 眼疾患の治療薬としてのｔｒｐｖ４阻害薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022024553A2 true BR112022024553A2 (pt) | 2023-01-24 |
Family
ID=79555653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022024553A BR112022024553A2 (pt) | 2020-07-16 | 2021-07-16 | Composto com atividade inibidora de trpv4 ou um sal farmaceuticamente aceitável do mesmo e seu uso, composição farmacêutica, método para se tratar uma doença da retina acompanhada de distúrbio do fluxo sanguíneo ou distúrbio celular, kit para uso na prevenção ou tratamento das doenças, marcador de doença para uma doença da retina, método para se detectar uma doença da retina, métodos de triagem para uma substância que suprime a expressão do gene de trpv4, uma que reduz o nível de expressão de uma proteína de trpv4 e uma que inibe a atividade de trpv4 e agente para prevenir ou tratar uma doença da retina |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230255965A1 (https=) |
| EP (1) | EP4183415A4 (https=) |
| JP (1) | JPWO2022014707A1 (https=) |
| KR (1) | KR20230041680A (https=) |
| CN (1) | CN115776890A (https=) |
| BR (1) | BR112022024553A2 (https=) |
| CA (1) | CA3189206A1 (https=) |
| MX (1) | MX2023000610A (https=) |
| TW (1) | TW202216143A (https=) |
| WO (1) | WO2022014707A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120641413A (zh) * | 2023-04-18 | 2025-09-12 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| WO2024217446A1 (zh) * | 2023-04-18 | 2024-10-24 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| WO2024217439A1 (zh) * | 2023-04-18 | 2024-10-24 | 河北乌图药业有限公司 | 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用 |
| CN116726013A (zh) * | 2023-04-25 | 2023-09-12 | 中国科学院大学深圳医院(光明) | Gsk2193874在防治痛性糖尿病周围神经病变中的应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409125A (en) | 1989-12-11 | 1995-04-25 | Aktiebolaget Astra | Unit dose container |
| DE4027320C2 (de) | 1990-08-29 | 1993-09-30 | Ursapharm Arzneimittel Gmbh | Fluid-Abgabeeinrichtung für keimfreies Fluid |
| EP0944530A1 (en) | 1996-12-09 | 1999-09-29 | Bausch & Lomb Incorporated | Single-use flexible container |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| TW586946B (en) | 2000-12-22 | 2004-05-11 | Novartis Ag | Process to improve stability |
| US20080139648A1 (en) | 2004-12-09 | 2008-06-12 | Santen Pharmaceutical Co., Ltd. | Product Containing Prostaglandin Having Fluorine Atom In Its Molecule |
| WO2007082262A2 (en) | 2006-01-11 | 2007-07-19 | Smithkline Beecham Corporation | Novel compounds |
| JP2009527495A (ja) | 2006-02-17 | 2009-07-30 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| JP5294601B2 (ja) | 2007-09-28 | 2013-09-18 | 小林製薬株式会社 | Ｔｒｐｖ４受容体抑制剤 |
| WO2009111680A1 (en) | 2008-03-07 | 2009-09-11 | Smithline Beecham Corporation | Trpv4 antagonists |
| WO2009146182A1 (en) | 2008-04-18 | 2009-12-03 | Smithkline Beecham Corporation | Trpv4 antagonists |
| WO2009146177A1 (en) | 2008-04-18 | 2009-12-03 | Smithkline Beecham Corporation | Trpv4 antagonists |
| WO2009139239A1 (ja) * | 2008-05-14 | 2009-11-19 | 日本電気株式会社 | 窒化物半導体レーザ及びその製造方法 |
| WO2010011912A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Trpv4 antagonists |
| JP5607046B2 (ja) | 2008-07-25 | 2014-10-15 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｔｒｐｖ４拮抗薬 |
| WO2011091407A1 (en) | 2010-01-25 | 2011-07-28 | Glaxosmithkline Llp | Trpv4 antagonists |
| WO2011091410A1 (en) | 2010-01-25 | 2011-07-28 | Glaxos Smithkline Llc | Trpv4 antagonists |
| WO2011119694A1 (en) | 2010-03-23 | 2011-09-29 | Glaxosmithkline Llc | Trpv4 antagonists |
| WO2011119693A1 (en) | 2010-03-23 | 2011-09-29 | Glaxosmithkline Llc | Trpv4 antagonists |
| WO2011119704A1 (en) * | 2010-03-23 | 2011-09-29 | Glaxosmithkline Llc | Trpv4 antagonists |
| WO2011119701A1 (en) | 2010-03-23 | 2011-09-29 | Glaxosmithkline Llc | Trpv4 antagonists |
| WO2012144661A1 (en) | 2011-04-20 | 2012-10-26 | Shionogi & Co., Ltd. | Aromatic heterocyclic derivative having trpv4-inhibiting activity |
| JO3154B1 (ar) | 2011-06-17 | 2017-09-20 | Glaxosmithkline Llc | عوامل مضادة لـ trpv4 |
| EP2720546B1 (en) | 2011-06-17 | 2016-04-06 | Glaxosmithkline Intellectual Property (No. 2) Limited | Spiro-cyclic trpv4 antagonists |
| US8927585B2 (en) | 2011-06-17 | 2015-01-06 | Glaxosmithkline Intellectual Property (No.2) Limited | TRPV4 antagonists |
| WO2013146754A1 (ja) | 2012-03-27 | 2013-10-03 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体 |
| CA2875842A1 (en) * | 2012-05-11 | 2013-11-14 | The University Of Utah Research Foundation | Compounds with trpv4 activity, compositions and associated methods thereof |
| WO2015046193A1 (ja) | 2013-09-25 | 2015-04-02 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体 |
| WO2015199206A1 (ja) | 2014-06-27 | 2015-12-30 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する６員環誘導体 |
| CN109153672B (zh) | 2016-05-19 | 2021-12-07 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | Trpv4拮抗剂 |
| RU2019110821A (ru) | 2016-09-20 | 2020-10-22 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Антагонисты trpv4 |
| TW201825458A (zh) | 2016-09-20 | 2018-07-16 | 英商葛蘭素史克智慧財產（第二）有限公司 | Ｔｒｐｖ４拮抗劑 |
| JP2019532054A (ja) | 2016-09-20 | 2019-11-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｔｒｐｖ４拮抗薬 |
| MX2017011166A (es) | 2017-08-31 | 2019-03-07 | Univ Mexico Nac Autonoma | Uso de los farmacos antagonistas del canal ionico transient receptor potential vaniloid 4 (trpv4) para el tratamiento del edema macular. |
| JP7195067B2 (ja) | 2018-06-20 | 2022-12-23 | 花王株式会社 | ロズマリン酸誘導体又はその塩 |
| WO2021170811A1 (en) * | 2020-02-27 | 2021-09-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treating eye disease using trpv4 antagonists |
| JP7692219B2 (ja) * | 2020-04-30 | 2025-06-13 | ラクオリア創薬株式会社 | Ｔｒｐｖ４拮抗薬としてのピリミジン－４（３ｈ）－オン誘導体 |
-
2021
- 2021-07-16 JP JP2022536464A patent/JPWO2022014707A1/ja active Pending
- 2021-07-16 TW TW110126328A patent/TW202216143A/zh unknown
- 2021-07-16 KR KR1020237000435A patent/KR20230041680A/ko active Pending
- 2021-07-16 CA CA3189206A patent/CA3189206A1/en active Pending
- 2021-07-16 BR BR112022024553A patent/BR112022024553A2/pt unknown
- 2021-07-16 MX MX2023000610A patent/MX2023000610A/es unknown
- 2021-07-16 WO PCT/JP2021/026829 patent/WO2022014707A1/ja not_active Ceased
- 2021-07-16 EP EP21842049.5A patent/EP4183415A4/en active Pending
- 2021-07-16 CN CN202180045312.2A patent/CN115776890A/zh active Pending
- 2021-07-16 US US18/014,367 patent/US20230255965A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202216143A (zh) | 2022-05-01 |
| WO2022014707A1 (ja) | 2022-01-20 |
| US20230255965A1 (en) | 2023-08-17 |
| JPWO2022014707A1 (https=) | 2022-01-20 |
| EP4183415A4 (en) | 2024-07-17 |
| MX2023000610A (es) | 2023-02-13 |
| KR20230041680A (ko) | 2023-03-24 |
| EP4183415A1 (en) | 2023-05-24 |
| CN115776890A (zh) | 2023-03-10 |
| CA3189206A1 (en) | 2022-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022024553A2 (pt) | Composto com atividade inibidora de trpv4 ou um sal farmaceuticamente aceitável do mesmo e seu uso, composição farmacêutica, método para se tratar uma doença da retina acompanhada de distúrbio do fluxo sanguíneo ou distúrbio celular, kit para uso na prevenção ou tratamento das doenças, marcador de doença para uma doença da retina, método para se detectar uma doença da retina, métodos de triagem para uma substância que suprime a expressão do gene de trpv4, uma que reduz o nível de expressão de uma proteína de trpv4 e uma que inibe a atividade de trpv4 e agente para prevenir ou tratar uma doença da retina | |
| Abdel Baki et al. | Minocycline synergizes with N-acetylcysteine and improves cognition and memory following traumatic brain injury in rats | |
| US20220125750A1 (en) | Methods of treating injuries or conditions related to cns edema | |
| CN101227926B (zh) | 组合物在制备治疗骨关节炎的药物中的应用 | |
| JP7519359B2 (ja) | レシニフェラトキシンを投与することによってパーキンソン病を処置するための方法 | |
| US10076522B2 (en) | Systems and methods for treating bacterial infection | |
| CN113490745A (zh) | 神经周施用树脂毒素治疗适应不良性疼痛 | |
| Bishop et al. | Combined intrastriatal dopamine D1 and serotonin 5-HT2 receptor stimulation reveals a mechanism for hyperlocomotion in 6-hydroxydopamine-lesioned rats | |
| US20170119760A1 (en) | Use of masitinib for the treatment of progressive supranuclear palsy | |
| US11571410B2 (en) | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder | |
| CN118284412A (zh) | 伴中度至重度焦虑和/或社交回避的自闭症谱系障碍受试者易怒症的治疗 | |
| BR112023022618A2 (pt) | Agentes compreendendo ácido (r)-2-[3-[[n-(benzoxazol-2-il)- n-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico, composição farmacêutica, kit e usos do dito ácido para aumentar a carnitina no sangue e prevenir e/ou tratar deficiência de carnitina, uma doença associada a uma diminuição na função mitocondrial, sarcopenia e uma doença na qual os sintomas são aliviados por um aumento no nível de carnitina no sangue | |
| ES2396976T3 (es) | Método y composición para tratar osteoartritis | |
| Duarte et al. | Caudal epidural anesthesia in mares after bicarbonate addition to a lidocaine–epinephrine combination | |
| BR112015032534B1 (pt) | Uso de compostos ou sal ou solvato farmaceuticamente aceitável dos mesmos | |
| BR112022019486A2 (pt) | Agente terapêutico para infecção por coronavírus | |
| CN110882240B (zh) | 作为急性缺血性中风的治疗剂的多酚衍生物化合物6-cepn | |
| Lachenmeier | Antiseptic drugs and disinfectants | |
| Kiroğlu et al. | Dipyrone ameliorates behavioural changes induced by unpredictable chronic mild stress: gender differences | |
| KR20230058615A (ko) | 파킨슨병의 운동 합병증 치료약 | |
| Puurunen | The effects of pharmacotherapy and training on functional recovery after global and focal cerebral ischemia in rats | |
| JP2009007278A (ja) | 線維筋痛症の治療薬 | |
| CN110755622A (zh) | 磷酸酶和张力蛋白同源物抑制剂在制备药物中的用途 | |
| RU2774970C2 (ru) | Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства | |
| Birnbaum et al. | Is preconditioning by nicotine responsible for the better prognosis in smokers with acute myocardial infarction? |